written on 22.04.2014

1Q EARNINGS PREVIEW: Gilead, Amgen, Biogen, Celgene, Lilly, AbbVie


The outlook for all six should be encouraging for investors, since the market recently has retreated from small and mid-cap biotechnology stock volatility in favor of more stable big pharma and large biotechs with positive news on the horizon. However,…